Biomarkers and Nicotine Pouches: Why Measuring Exposure Matters for Evidence-Based Regulation

As nicotine pouches continue to emerge within tobacco harm reduction discussions, policymakers are increasingly faced with a fundamental question: how should the health risks of these products be assessed? Public debate often reduces the issue to a simple question of whether nicotine pouches are “safe” or “unsafe.” While understandable, this framing overlooks how modern toxicology…

Supporting Women Who Struggle to Quit Smoking During Pregnancy: Why Evidence-Based Conversations Matter

Smoking during pregnancy remains one of the most significant preventable causes of adverse maternal and infant health outcomes worldwide. It increases the risk of miscarriage, placental complications, preterm birth, low birth weight, stillbirth, and sudden infant death syndrome, while also contributing to long-term health consequences for both mother and child. For healthcare professionals, the objective…

Youth Protection and Harm Reduction: What the Latest FDA Data Means for Nicotine Policy

Every year, the United States Food and Drug Administration’s National Youth Tobacco Survey (NYTS) provides one of the most closely watched snapshots of tobacco and nicotine use among young people. The survey plays an important role in informing regulatory discussions not only in the United States but also globally, as policymakers increasingly look to youth…

New Oral Health Study Adds Important Evidence But Not the Final Answer on Nicotine Pouches

As tobacco-free nicotine pouches become more widely available, understanding their effects on oral health has become an important area of scientific research. Every new study contributes to a growing evidence base that should inform clinicians, regulators, and policymakers. A recently published study in Oral Diseases examined oral lesions and dental status among users of tobacco-free…

Beyond the Headlines: Why the Nicotine Pouch Debate Is Really About Risk, Not Nicotine

Recent commentary from researchers at Stanford University has reignited debate over nicotine pouches, describing them as the latest strategy by the tobacco industry to sustain nicotine addiction while raising concerns about youth appeal, flavours, marketing, and the absence of long-term health data. These concerns reflect genuine public health priorities and deserve careful consideration. However, the…

What Does the Science Say About Nicotine Pouches? Lower Toxicant Exposure, Remaining Uncertainties, and the Case for Proportionate Regulation

As nicotine pouches continue to expand across global markets, policymakers and public health stakeholders are increasingly asking important questions about their safety profile, long-term health implications, and appropriate regulation. A recent review published in Tobacco Induced Diseases, “Research on the Safety Risk of Oral Nicotine Products and Its Prospects,” contributes to this growing evidence base…

Who Is Considering Switching to Nicotine Pouches?

New Research Offers Insights into Consumer Interest and Smoking Status As nicotine pouches continue to gain attention from regulators, researchers, and public health stakeholders, an important question remains: who is actually interested in using them? Much of the policy debate surrounding nicotine pouches focuses on potential risks, youth uptake, and regulatory controls. However, understanding who…

What Does the Evidence Say About Nicotine Pouches?

Examining the Scientific Case for Tobacco Harm Reduction As nicotine pouches become an increasingly prominent feature of nicotine policy discussions worldwide, debate often moves faster than the science itself. Regulators, public health stakeholders, researchers, and policymakers are grappling with important questions about risk, cessation, consumer behaviour, and appropriate regulatory frameworks. While long-term epidemiological evidence is…

Predicting Nicotine Delivery: What a New Scientific Model Could Mean for Product Assessment and Regulation

As nicotine products continue to evolve, regulators and researchers face a recurring challenge: how can the performance of new products be evaluated efficiently, accurately, and consistently without relying exclusively on costly and time-consuming human clinical studies? A newly published study in Scientific Reports offers an interesting contribution to that discussion. Rather than focusing on consumer…

When the IMF Recognises the Risk Continuum: Why Nicotine Products Should Not Be Regulated as if They Are Equally Harmful

Discussions about nicotine regulation often become polarized. Some policymakers argue that all nicotine products should be treated similarly because they contain an addictive substance. Others argue that regulation should reflect differences in risk between products. A recent analysis from the International Monetary Fund (IMF) offers an important contribution to this debate. Published in Taxing Harmful…